Urolithin A vs. PQQ: How These Two Mitochondrial Supplements Compare

Two compounds have attracted serious scientific interest for their effects on mitochondrial health: urolithin A, a metabolite produced when gut bacteria process certain plant polyphenols, and pyrroloquinoline quinone (PQQ), a redox-active compound found in small amounts in some foods. Both are sold as supplements aimed at supporting cellular energy, healthy aging, and physical function, but they work through distinct biological pathways.

Understanding the difference matters if you’re trying to make an informed decision. This article breaks down what the current evidence shows for each compound, where their mechanisms overlap, where they diverge, and what remains genuinely uncertain. Neither compound is a cure for aging or any disease, and the research, while promising, is still maturing.

How Urolithin A Works: Cleaning Up Damaged Mitochondria

Urolithin A’s primary mechanism is mitophagy: a selective cellular process that identifies and removes damaged or dysfunctional mitochondria. Think of it as quality control for the cell’s energy-generating machinery. As mitochondria age or accumulate damage, they become less efficient and can release signals that drive inflammation. Mitophagy clears these out, making room for healthier replacements through a process called mitochondrial biogenesis.

A 2024 systematic review of human research found that urolithin A upregulated some mitochondrial genes and markers of autophagy, although it did not affect mitochondrial biogenesis or maximal ATP production ^[3]. A randomized, placebo-controlled trial published in Nature Aging in 2025 found a very small rise (0.50 percentage points) in the share of naive-like CD8+ T cells over 4 weeks at 1,000 mg a day; the trial was funded by Amazentis and measured cell markers, not clinical outcomes ^[1]. Separately, a mouse study reported that urolithin A can stimulate mitochondrial biogenesis through estrogen receptor signaling pathways in brain tissue, although the human systematic review found no effect on mitochondrial biogenesis ^[3][4].

One complication worth noting: urolithin A is not consumed directly from food in meaningful quantities. It is produced by gut bacteria when you eat pomegranates, walnuts, or certain berries. Significant variation in gut microbiome composition means many people produce little to no urolithin A from diet alone, which is part of the argument for supplementation, though supplement absorption and bioequivalence to endogenously produced urolithin A is still being characterized.

How PQQ Works: Antioxidant Activity and Mitochondrial Signaling

PQQ is a small molecule with potent redox (electron-transferring) activity. It is found in trace amounts in fermented foods, green tea, and some vegetables. Its proposed mitochondrial benefits center on two mechanisms: acting as an antioxidant that protects mitochondrial membranes from oxidative damage, and activating signaling pathways, particularly through PGC-1α, that stimulate mitochondrial biogenesis.

A 2021 review classified PQQ as a ‘vitamin-like’ accessory factor, noting its role in supporting mitochondrial function and its potential relevance to inflammation and disease prevention, while also emphasizing that more human trial data is needed ^[5]. A 2013 human study found that dietary PQQ supplementation altered inflammation markers and indicators of mitochondrial-related metabolism in healthy subjects ^[2]. More recent research has shown PQQ protecting mitochondrial function in cells undergoing premature senescence ^[6] and reducing mitochondrial damage in radiation-injury models via a MOTS-c-dependent pathway ^[7].

Unlike urolithin A, PQQ does not induce mitophagy in the same way. Its primary angle is protecting existing mitochondria from damage and promoting new mitochondrial growth, without the selective degradation step that characterizes urolithin A’s mechanism.

Where the Mechanisms Overlap and Where They Differ

Both compounds ultimately aim at improving mitochondrial quantity and quality, but they approach the problem from different directions. Urolithin A triggers the removal of damaged mitochondria first, then supports replacement with healthier ones. PQQ focuses more on protecting mitochondria from oxidative stress and directly stimulating new mitochondrial production. In that sense, they are not simply redundant: urolithin A is more of a ‘clearance’ agent and PQQ more of a ‘protection and growth’ agent.

PQQ is described as acting on mitochondrial biogenesis through PGC-1α. For urolithin A, a 2024 systematic review of human studies found no effect on mitochondrial biogenesis ^[3]. Urolithin A engages autophagy machinery (specifically the p62/SQSTM1 pathway, as reported in a mouse model of retinal degeneration ^[8]), while PQQ appears to work more directly on redox signaling and cellular energy sensing.

For muscle health specifically, a 2024 Sports Medicine review noted that mitochondrial quality is a key target for preserving physical function with age, and that compounds supporting both mitophagy and biogenesis may be complementary rather than interchangeable ^[9]. This suggests the two compounds might theoretically act on different parts of the same problem, though head-to-head human trials comparing them directly do not yet exist.

What the Human Evidence Actually Shows

Urolithin A has the larger and more recent body of controlled human trial data. The 2025 Nature Aging trial (50 people, 4 weeks, 1,000 mg a day, funded by Amazentis) reported a very small shift in T-cell markers; it did not measure clinical immune outcomes ^[1]. The 2024 systematic review of five human studies reported increases in muscle strength and endurance but no effect on physical function, cardiovascular outcomes, maximal mitochondrial ATP production or biogenesis ^[3]. Animal and cell research extends to contexts including retinal neurodegeneration ^[8], cognitive protection ^[4], and cancer immunology ^[10].

That larger body of data still has limits. In both the 88-person middle-aged trial and the 66-person older-adult trial, the primary endpoints were missed, and the strength and endurance gains were secondary endpoints. Both trials were funded by Amazentis, the maker of Mitopure ^[16][17].

PQQ’s human evidence is thinner but real. The most-cited human study dates to 2013 and showed changes in inflammation and mitochondrial metabolism markers after dietary PQQ ^[2]. More recent work has focused on cell and animal models, including stem cell mitochondrial preservation ^[11] and neuroprotective effects in preclinical models of neurodegenerative disease ^[12]but large, well-powered human trials are lacking. This is an honest gap in the literature.

Neither compound has been tested in a large-scale, long-term randomized controlled trial for hard endpoints like mortality, cardiovascular events, or functional independence. The evidence for both is promising but preliminary when held to that standard.

Potential Use Cases: Are They Targeting the Same People?

The research profiles suggest somewhat different primary use cases, at least based on where the evidence is strongest so far. The urolithin A human data are mostly small, largely company-funded trials of muscle function, immune-cell markers and mitochondrial biomarkers ^{[16][17][1][3]}making it potentially relevant for older adults concerned about physical function, immune resilience, or cellular aging more broadly ^[3][1].

PQQ’s evidence points more toward antioxidant protection, cognitive support in neurodegenerative contexts, and mitochondrial preservation in stress or damage scenarios ^[12][7]. The ‘vitamin-like’ framing in the literature positions PQQ as an accessory factor important in health and disease prevention, and its authors describe it as having strong potential as a therapeutic nutraceutical ^[5].

Some supplement formulators combine the two compounds on the rationale that their mechanisms are complementary: clearance plus protection. This is theoretically coherent, but there are no published human studies testing the combination specifically, so the additive or synergistic claim remains speculative.

Safety and Practical Considerations

Urolithin A has been evaluated in human trials at doses ranging from 10 mg to 1000 mg per day for 28 days to 4 months, and the unrelated adverse events reported were mild or moderate ^[3][1]. It is generally described as well-tolerated. PQQ has also shown a reasonable short-term safety profile in the available human research at typical supplemental doses (10 to 20 mg/day), though the 2013 study was relatively small and short-duration ^[2].

Long-term safety data for both compounds in large, diverse populations is still limited. Neither compound has established official recommended dietary intake levels or approved medical uses. People with chronic health conditions, those taking medications that affect cellular metabolism or immune function, and pregnant or breastfeeding individuals should consult a healthcare provider before using either supplement.

A Note on the Evidence

The evidence for both urolithin A and PQQ, while growing, is based on studies that are mostly short-term, small in scale, or conducted in cell and animal models: neither compound has established long-term safety data or proven clinical benefits for any medical condition. This article is for informational purposes only and does not constitute medical advice; consult a qualified healthcare provider before adding any new supplement to your routine, particularly if you are pregnant, have a chronic health condition, or take medications.

Frequently Asked Questions

What is the main difference between urolithin A and PQQ?

Urolithin A primarily triggers mitophagy, the selective removal of damaged mitochondria, and in a systematic review of human studies it upregulated markers of autophagy without affecting mitochondrial biogenesis ^[3]. PQQ works mainly as a redox-active antioxidant that protects mitochondria from oxidative damage and stimulates mitochondrial biogenesis through different upstream signals ^[5]. They target related but distinct aspects of mitochondrial quality control.

Which compound has stronger human evidence?

Urolithin A currently has the more robust human trial evidence, including a 2024 systematic review of human studies ^[3] and a 2025 randomized, placebo-controlled trial published in Nature Aging ^[1]. PQQ’s most directly relevant human study was published in 2013 ^[2], and more recent research has largely been in cell cultures or animal models.

Can urolithin A and PQQ be taken together?

There is no published human research testing the combination directly. The mechanisms are theoretically complementary, urolithin A clears damaged mitochondria while PQQ may protect and grow healthy ones, but any claim of synergistic benefit in humans is speculative at this stage. It is reasonable to discuss combination use with a healthcare provider.

Does PQQ have antioxidant benefits beyond mitochondria?

PQQ has broad redox activity and has been studied for anti-inflammatory effects and neuroprotective properties beyond mitochondria specifically. A 2021 review described it as having relevance to health and disease prevention through multiple mechanisms ^[5], and 2025 research explored its role in neurodegenerative disease models ^[12]. However, most of this research is preclinical.

Why can't most people get enough urolithin A from food?

Urolithin A is not present in food directly: it is produced by gut bacteria that metabolize precursor compounds called ellagitannins found in pomegranates, walnuts, and some berries. Substantial individual variation in gut microbiome composition means many people produce very little urolithin A even with adequate dietary precursor intake, which is one rationale for direct supplementation ^[3].

Are there any known safety concerns with either supplement?

Both compounds have shown acceptable short-term safety profiles in published research at typical supplemental doses, with no serious adverse events reported in urolithin A trials ^[1] and no significant concerns noted in the primary PQQ human study ^[2]. Long-term safety data in large populations is lacking for both. Anyone with chronic health conditions or taking prescription medications should consult a doctor before starting either supplement.

References

1. Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
2. Harris CB et al. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. The Journal of nutritional biochemistry (2013). PMID 24231099
3. Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
4. Chen P et al. Urolithin A protects against domoic acid-induced cognitive deficits via promoting estrogen receptor-α-mediated mitochondrial biogenesis signaling in mice. Free radical biology & medicine (2025). PMID 40818743
5. Jonscher KR et al. Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention. Biomolecules (2021). PMID 34680074
6. Gao Y et al. Pyrroloquinoline quinone (PQQ) protects mitochondrial function of HEI-OC1 cells under premature senescence. npj aging (2022). PMID 35927260
7. Zhang Y et al. Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner. Journal of agricultural and food chemistry (2024). PMID 39259217
8. Jiménez-Loygorri JI et al. Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration. Molecular neurodegeneration (2024). PMID 38890703
9. Broome SC et al. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Sports medicine (Auckland, N.Z.) (2024). PMID 39060742
10. Denk D et al. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity (2022). PMID 36351375
11. Liu S et al. Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway. Stem cell research & therapy (2024). PMID 38581065
12. Xie T et al. Current study on Pyrroloquinoline quinone (PQQ) therapeutic role in neurodegenerative diseases. Molecular biology reports (2025). PMID 40234255
13. Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
14. Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
15. Peter M. J. Quinn et al. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathologica Communications (2020). PMID 33168089
16. Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
17. Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.